Sorin denies acquisition bid for Fidia:
This article was originally published in Clinica
Sorin has rejected Italian press speculation linking it to a acquisition bid for the pharmaceutical company Fidia. The Italian biomedical company has stressed that it has no intention to diversify into the drugs industry. Il Mattino had linked the involvement in the bid of Snia's managing director - and Sorin's previous managing director - Umberto Rosa, to the possible exit of Sorin from Snia (see Clinica No 806, p 7). Snia is the Fiat chemical holding which owns Sorin. Dr Ezio Garibaldi, managing director of the Sorin group, emphasised that there are no plans for Sorin to leave Snia, although Snia may exit Fiat.
You may also be interested in...
As the first emergency use authorization is granted, Pfizer and Moderna stand accused of neglecting poorer nations as wealthy countries snap up early access to COVID-19 vaccines.
The FDA has released final guidance on “Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA” for the industry. The guidance brings clarity and aims at facilitating product development meetings between the FDA and the ANDA applicants for complex products.
By handing out free supplements to the clinically vulnerable, the UK government is effectively endorsing the use of vitamin D to reduce the risk and/or severity of COVID-19, although it says more research is needed.